Spots Global Cancer Trial Database for Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux
Official Title: Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux
Study ID: NCT00609284
Conditions
Study Description
Brief Summary: The aim of the trial is to study the efficacy of adding concomitant chemotherapy (carboplatin/5FU) to Erbitux-radiotherapy in patients with locally advanced head and neck cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Centre hospitalier Annecy, Annecy, , France
Centre Jean Perrin, Clermont Ferrand, , France
Centre Guillaume Le Conquerant, Le Havre, , France
Centre hospitalier de Bretagne Sud, Lorient, , France
Institut Gustave Roussy, Villejuif, , France
Contact Details
Name: Jean BOURHIS, MD, PhD
Affiliation: GORTEC
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
